Disclaimer:

Disclaimer: The blog posts and comments on this blog and posts on social networks are not investment recommendation, are provided solely for informational purposes, and do not constitute an offer or solicitation to buy or sell any securities. The opinions expressed on the blog are Petar Posledovich's. Petar Posledovich does not guarantee the accuracy of the information presented on this blog and social networks. The information presented is "as is". The blog is stocks analysis and valuation, Bitcoin, Cryptocurrencies, Artificial Intelligence, AI, deep-learning focused. Independent, unbiased AI insights. Petar Vladimirov Posledovich is not liable for any investment losses incurred by reading and interpreting blog posts on this blog and posts on social networks. Conflicts of interest: I may possess some of the securities, currencies or their derivatives mentioned in the blog post and posts on social networks! The blog is property of Wolfteam Ltd. www.wolfteamedge.com Respectfully yours, Petar Posledovich

Tuesday, August 9, 2022

Bavarian Nordic Monkeypox Vaccine Producer Valuation


Bavarian Nordic A/S, the only producer of an approved vaccine for monkeypox is currently valued at circa 3.4 billion USD.

I estimate the intrinsic value of Bavarian Nordic is 45 billion USD.

Actually, it is quite possible that monkeypox is transmitted by air, not only via physical contact.

And if the coronavirus is to be an example, the monkeypox could show remarkable resiliency, agility, adaptability and ability to change, mutate to survive.

Since Bavarian Nordic is the only producer of an approved monkeypox vaccine, if monkeypox becomes a global pandemic, which the World health Organization said it actually is the demand for Bavarian Nordic's monkey pox vaccine, namely Jynneos could prove huge.

Which naturally would accrue substantial wealth in the next 3 to 5 years to Bavarian Nordic.

No comments: